Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). [Phase 3]
Phase 3 trial comparing Polatuzumab Vedotin plus Bendamustine and Rituximab versus Bendamustine and Rituximab alone in Chinese patients with…
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL [Phase 1, Phase 2]
Phase 1/2 trial evaluating KRT-232 in combination with acalabrutinib for relapsed/refractory DLBCL and CLL; status not disclosed.
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor [Phase 2]
Phase 2 trial evaluating RCHOP chemotherapy with BBB permeabilization by t-NGR necrosis factor in diffuse large B-cell lymphoma; study compl…
-
CLINICAL_TRIALS trial_result · 2022-07-25Clinical Trial Update: ChiCGB vs BEAM in High-risk or R/R Lymphomas [Phase 3]
Phase 3 clinical trial comparing ChiCGB to BEAM in high-risk or refractory/relapsed lymphomas is listed with phase 3 and unknown status.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with RICE for relapsed/refractory diffuse large B-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating axicabtagene ciloleucel as first-line therapy for high-risk diffuse large B-cell lymphoma has completed, with res…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating orelabrutinib in combination with Gemox for refractory/relapsed diffuse large B-cell lymphoma is underwa…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection [Phase 2]
A Phase 2 trial evaluated EPOCH chemotherapy with Rituximab for HIV-associated non-Hodgkin lymphoma, including diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. [Phase 2]
Phase 2 trial comparing ZR2 to a R-CHOP-like regimen in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma [Phase 2]
Phase 2 trial update for therapy in untreated DLBCL patients across risk groups; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial [Phase 2]
A multicenter randomized Phase II trial evaluating treatment options for diffuse large B-cell lymphoma in vulnerable or frail elderly patien…
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. [Phase 2, Phase 3]
Phase II randomized study comparing BR-DHAP vs R-DHAP induction therapy in relapsed/refractory diffuse large B-cell lymphoma patients eligib…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial [Phase 2]
Phase 2 clinical trial evaluating rituximab plus zanubrutinib and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma; effica…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion [Phase 2]
Phase 2 trial evaluating addition of nivolumab to anti-CD-19 CAR-T cells in patients with B cell lymphoma undergoing lymphodepletion.
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating laboratory-treated T cells in relapsed or refractory B-cell malignancies and acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1]
Phase 1 first-in-human trial of GSK3368715 in solid tumors and diffuse large B-cell lymphoma has been terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]
Phase 3 trial comparing rituximab biosimilar HLX01 plus CHOP versus rituximab with CHOP in previously untreated CD20+ diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations [Phase 2]
Phase 2 trial evaluating CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including MYC-altered cases, has completed with resu…
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update investigating toripalimab in combination with rituximab followed by R-CHOP for elderly patients with untreated diffuse…
-
CLINICAL_TRIALS trial_result · 2022-04-11Clinical Trial Update: A Phase I Trial of AZD3965 in Patients With Advanced Cancer [Phase 1]
Phase I trial of AZD3965 in adults with advanced cancer, including diffuse large B-cell lymphoma and Burkitt lymphoma, completed with result…
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) [Phase 2]
Phase 2 clinical trial evaluating anti-PD-1 antibody with chidamide and rituximab in relapsed or refractory diffuse large B-cell lymphoma (D…
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL [Phase 2]
Phase 2 trial evaluating camrelizumab plus R-CHOP in untreated primary extranodal diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-04-01Clinical Trial Update: Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL [Phase 2]
Phase 2 trial evaluating pre-phase treatment before R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: ZR-CHOP in DLBCL With Specific Gene Abnormality [Phase 2]
Phase 2 trial update of ZR-CHOP in diffuse large B-cell lymphoma with a specific gene abnormality.